<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622905</url>
  </required_header>
  <id_info>
    <org_study_id>FNMI-002</org_study_id>
    <nct_id>NCT03622905</nct_id>
  </id_info>
  <brief_title>ADvance II Study: DBS-f in Patients With Mild Alzheimer's Disease</brief_title>
  <official_title>ADvance II: A 12-month Double-blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Deep Brain Stimulation of the Fornix (DBS-f) in Patients With Mild Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Functional Neuromodulation Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Functional Neuromodulation Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary efficacy objective of this study is to test the hypothesis that DBS-f stimulation
      (ON) will slow cognitive and functional progression of AD, as compared to no stimulation
      (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated
      Alzheimer's disease rating scale (iADRS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Over Time at 12 months on the Ingegrated Alzheimer's Disease Rating Scale (iADRS) [ Time Frame: From Baseline to month 12 ]</measure>
    <time_frame>12 months</time_frame>
    <description>The iADRS is a composite tool that combines scores from the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) and the Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living (ADCS-iADL). It measures both cognition and function and demonstrates acceptable psychometric properties, and is effective in capturing both disease progression and separation of placebo and active treatment effect. The iADRS score ranges from 0 to 146 with lower scores indicating worse performance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Over Time at 12 months on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) [ Time Frame: From Baseline to month 12 ]</measure>
    <time_frame>12 months</time_frame>
    <description>The CDR-SB is a validated clinical assessment of global function in patients with AD. Impairment is scored in each of 6 cognitive categories on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2, and severe = 3. The 6 individual category ratings, or &quot;box scores&quot;, can be added together to give the CDR-SB which ranges from 0 to 18 (severe impairment).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>DBS On</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DBS system On</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DBS Off</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>DBS System Off</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS-f On</intervention_name>
    <description>Deep Brain Stimulation of the fornix</description>
    <arm_group_label>DBS On</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DBS Off</intervention_name>
    <description>Deep Brain Stimulation of the fornix turned off</description>
    <arm_group_label>DBS Off</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent signed by the subject and caregiver.

          2. At least 65 years old

          3. Probable Alzheimer's disease according to the National Institute of Aging Alzheimer's
             disease Association criteria.

          4. Mild dementia according to the Clinical Dementia Rating (CDR) global rating of 0.5 or
             1 at screening.

          5. ADAS-cog-11 score of 10-24 inclusive at screening AND baseline (with a score ≥ 4 on
             ADAS-cog item 1).

          6. Confirmation of Alzheimer's disease based on CSF biomarkers.

          7. The patient has an available caregiver or other appropriate knowledgeable informant
             who can reliably report on daily activities and function and signs the informed
             consent for participation as such.

          8. Patient must be a good surgical candidate for placement of a deep brain stimulator as
             judged by the DBS surgical team.

          9. Fluency (oral and written) in the language in which standardized tests will be
             administered.

         10. The patient is either

               1. taking a stable dose of cholinesterase inhibitor (AChEI) medication (donepezil,
                  galantamine, or rivastigmine) for at least 60 days prior to signing the informed
                  consent form OR

               2. the patient has previously had an intolerance/failure to cholinesterase inhibitor
                  medications that can be documented AND there is no intention to modify the dose
                  over the course of the study (NOTE: These medications may NOT be initiated,
                  discontinued or modified during the 12-month control period).

        Exclusion Criteria:

          1. NPI total score ≥ 10 or score ≥ 4 in any NPI domain (clinically significant
             neuropsychiatric symptoms). Apathy score ≥ 4 acceptable.

          2. Modified Hachinski ischemia scale score &gt; 4 at screening.

          3. At risk for suicide in the opinion of the investigator or the subject answers &quot;yes&quot; to
             &quot;Suicidal Ideation&quot; Item 4 or 5 on the C-SSRS (at the time of evaluation) at the
             screening visit or attempted suicide within the last 2 years.

          4. Suffers from a major psychiatric disorder such as schizophrenia, bipolar disorder or
             major depressive disorder, or has current alcohol or substance abuse based on
             psychiatric consultation at screening visit.

          5. History of moderate or more severe traumatic brain injury in the 2 years prior to
             signing the consent to participate in the study.

          6. History of brain tumor, subdural hematoma, or other clinically significant (in the
             judgment of the investigator) space-occupying lesion on CT or MRI.

          7. History of seizure disorder.

          8. Contraindications for PET scanning (e.g., insulin dependent diabetes).

          9. Contraindications for MRI scanning, including implanted metallic devices (e.g.
             non-MRI-safe cardiac pacemaker or neurostimulator; some artificial joints metal pins;
             surgical clips; or other implanted metal parts), or claustrophobia or discomfort in
             confined spaces.

         10. Radiation exposure in the 1 year prior to signing the informed consent form that, in
             combination with the radiation exposure from this study, would exceed 5 rem.

         11. Abnormal cardiovascular or neurovascular disorder that, in the opinion of the
             investigator would preclude participation in the study.

         12. Currently prescribed any non-AD medications that, in the opinion of the investigator
             would preclude participation in the study.

         13. Is unable or unwilling to comply with protocol follow-up requirements.

         14. Has a life expectancy of &lt; 1 year.

         15. Is actively enrolled in another concurrent clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kristen Drake</last_name>
    <phone>214-543-8321</phone>
    <email>kdrake@fxneuromod.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robyn Moxon</last_name>
    <email>rmoxon@fxneuromod.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margeaux Snell</last_name>
      <phone>800-392-2222</phone>
    </contact>
    <investigator>
      <last_name>Anna Burke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Oviedo</last_name>
      <phone>323-865-9873</phone>
      <email>sandra.oviedo@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Darrin Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vyvian Ngo</last_name>
      <phone>650-498-0817</phone>
      <email>vyviann@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Casey Halpern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camille Swartz</last_name>
      <phone>352-273-5612</phone>
      <email>Cami.Swartz@neurology.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Adolfo Ramirez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Samson</last_name>
      <phone>813-974-1201</phone>
      <email>jsamson@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Fils, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Kim</last_name>
      <phone>410-550-4696</phone>
      <email>jkim587@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Jenkins</last_name>
      <phone>336-716-3842</phone>
      <email>wejenkin@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Adrian Laxton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Bertsch</last_name>
      <phone>401-793-9177</phone>
      <email>kbertsch@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>Wael Asaad, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashleigh Smith</last_name>
      <phone>512-270-9039</phone>
      <email>Ashleigh.smith@austin.utexas.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Buchanan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Schmidt, RN</last_name>
      <phone>414-955-0674</phone>
      <email>kaschmidt@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Franczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Lenis, BHA</last_name>
      <phone>(416) 603-5800</phone>
      <phone_ext>2797</phone_ext>
      <email>Martha.lenis@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Andres Lozano, MD, PhD, FRCSC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätmedizin Charité Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Altendorf</last_name>
      <phone>004930450660226</phone>
      <email>claudia.altendorf@charite.de</email>
    </contact>
    <investigator>
      <last_name>Andrea Kühn, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Köln</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elfriede Stubbs</last_name>
      <phone>0049-221-47898842</phone>
      <email>elfriede.stubbs@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Veere Visser-Vandewalle, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Neurologie Universitätsklinikum</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birte Hackelberg</last_name>
      <phone>0049-431-50023989</phone>
      <email>Birte.Hackelberg@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Steffen Paschen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urte Schneider</last_name>
      <phone>0049-391-6724601</phone>
      <email>Urte.Schneider@dzne.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Voges, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Technische Universität München</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friederike Schels</last_name>
      <phone>00498941404276</phone>
      <email>Friederike.schels@mri.tum.de</email>
    </contact>
    <investigator>
      <last_name>Timo Grimmer, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Marie Ilita</last_name>
      <phone>0049-931-20124805</phone>
      <email>Ilita_A@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Cordula Matthies, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 1, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Probable Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

